Reveals latest discoveries related to the molecular mechanisms of proteasome inhibitor resistance
Discusses proteasome inhibitor resistance in multiple contexts, including multiple myeloma, leukemia, mantle cell lymphoma, melanoma and other cancers
Explores multiple, cutting-edge strategies to overcome resistance
Reveals latest discoveries related to the molecular mechanisms of proteasome inhibitor resistance
Discusses proteasome inhibitor resistance in multiple contexts, including multiple myeloma, leukemia, mantle cell lymphoma, melanoma and other cancers
Explores multiple, cutting-edge strategies to overcome resistance
Includes supplementary material: sn.pub/extras
Q. Ping Dou, Ph.D. is Professor of Pathology, Cancer Biology and Pharmacology at Wayne State University School of Medicine. Dr. Dou's laboratory is one of the first to report that proteasome inhibitors rapidly induce tumor cell apoptosis, selectively activate the cell death program in oncogene-transformed, but not normal or untransformed cells and are able to trigger apoptotic death in human cancer cells that are resistant to various anticancer agents. He also serves on multiple editorial boards, including The Open Leukemia Journal, Journal of Clinical Oncology, Frontiers of Bioscience, to name a few.
The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.
This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.
Preface - Q Ping Dou
Proteasome inhibitors and lessons learned from their mechanisms of action and resistance in human cancer - Sara M. Schmitt, Rahul R. Deshmukh, Q. Ping Dou
Resistance to proteasome inhibitors in multiple myeloma - Francesca Cottini MD, Anna Guidetti MD, Claudia Paba Prada MD, Teru Hideshima MD PhD, Michelle Maglio, Cindy Varga MD, Dharminder Chauhan JD PhD, Jacob Laubach MD, Kenneth C Anderson MD, Paul G Richardson MD
Overcoming bortezomib resistance: a review on the second generation proteasome inhibitor carfilzomib in the treatment of multiple myeloma - Hans C. Lee, M.D., and Robert Z. Orlowski, Ph.D., M.D.
Proteasome inhibitors in the treatment of multiple myeloma and amyloidosis - Jeffrey A. Zonder, MD
Profiling bortezomib resistance in multiple myeloma: implications in personalized pharmacotherapy - Amit Mitra, Holly Stessman, John Shaughnessy, and Brian Van Ness
Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition - Michael Batalo, Prithviraj Bose, Beata Holkova, Steven Grant
Pre-clinical studies on the molecular basis of bortezomib resistance and modalities to overcome resistance in hematological malignancies - Jacqueline Cloos, Denise Niewerth, Gerrit Jansen
Overcoming inherent resistance to proteasome inhibitors in head and neck cancer: Challenges and new approaches - Jason I. Kass, Jennifer R. Grandis and Daniel E. Johnson
Targeting the proteasome pathway for the treatment of solid tumors - Nisar Ahmad, Elias Anaissie and James J. Driscoll
The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.
This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.
Proteasome inhibitors and lessons learned from their mechanisms of action and resistance in human cancer.- Resistance to proteasome inhibitors in multiple myeloma.- Overcoming bortezomib resistance: a review on the second generation proteasome inhibitor carfilzomib in the treatment of multiple myeloma .- Proteasome inhibitors in the treatment of multiple myeloma and amyloidosis.- Profiling bortezomib resistance in multiple myeloma: implications in personalized pharmacotherapy.- Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition.- Pre-clinical studies on the molecular basis of bortezomib resistance and modalities to overcome resistance in hematological malignancies.- Overcoming inherent resistance to proteasome inhibitors in head and neck cancer: Challenges and new approaches.- Targeting the proteasome pathway for the treatment of solid tumors.- Oxidative stress and the proteasome: mechanism and the therapeutic relevance.- Proteotoxic stress and proteasome inhibitor efficacy and resistance.- Proteasome inhibitors versus E3 ligase inhibitors for cancer therapy.- Novel ubiquitin E3 ligases as targets for cancer therapy: Focus on breast cancer associated gene 2 (BCA2).- The 26S proteasomal ATPases: structure, function, regulation and potential for cancer therapies.- Deubiquitinating enzymes as novel targets for cancer therapies
Über den Autor
Q. Ping Dou, Ph.D. is Professor of Pathology, Cancer Biology and Pharmacology at Wayne State University School of Medicine. Dr. Dou's laboratory is one of the first to report that proteasome inhibitors rapidly induce tumor cell apoptosis, selectively activate the cell death program in oncogene-transformed, but not normal or untransformed cells and are able to trigger apoptotic death in human cancer cells that are resistant to various anticancer agents. He also serves on multiple editorial boards, including The Open Leukemia Journal, Journal of Clinical Oncology, Frontiers of Bioscience, to name a few.
Inhaltsverzeichnis
Proteasome inhibitors and lessons learned from their mechanisms of action and resistance in human cancer.- Resistance to proteasome inhibitors in multiple myeloma.- Overcoming bortezomib resistance: a review on the second generation proteasome inhibitor carfilzomib in the treatment of multiple myeloma .- Proteasome inhibitors in the treatment of multiple myeloma and amyloidosis.- Profiling bortezomib resistance in multiple myeloma: implications in personalized pharmacotherapy.- Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition.- Pre-clinical studies on the molecular basis of bortezomib resistance and modalities to overcome resistance in hematological malignancies.- Overcoming inherent resistance to proteasome inhibitors in head and neck cancer: Challenges and new approaches.- Targeting the proteasome pathway for the treatment of solid tumors.- Oxidative stress and the proteasome: mechanism and the therapeutic relevance.- Proteotoxic stress and proteasome inhibitor efficacy and resistance.- Proteasome inhibitors versus E3 ligase inhibitors for cancer therapy.- Novel ubiquitin E3 ligases as targets for cancer therapy: Focus on breast cancer associated gene 2 (BCA2).- The 26S proteasomal ATPases: structure, function, regulation and potential for cancer therapies.- Deubiquitinating enzymes as novel targets for cancer therapies
Klappentext
The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.
This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.
Reveals latest discoveries related to the molecular mechanisms of proteasome inhibitor resistance
Discusses proteasome inhibitor resistance in multiple contexts, including multiple myeloma, leukemia, mantle cell lymphoma, melanoma and other cancers
Explores multiple, cutting-edge strategies to overcome resistance
Includes supplementary material: sn.pub/extras
